Kangbuk samsung hospital
Seoul, South Korea
NCT Number: NCT06174779
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Phase 3
Seoul, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Test drug
Placebo drug
Time frame: baseline, 40 weeks
Time frame: baseline, 40 weeks
Time frame: baseline, 24 weeks, 64 weeks
Time frame: baseline, 24 weeks, 64 weeks
Time frame: baseline, 24 weeks, 40 weeks, 64 weeks
Time frame: baseline, 24 weeks, 40 weeks, 64 weeks
Time frame: baseline, 24 weeks, 40 weeks, 64 weeks
Time frame: baseline, 24 weeks, 40 weeks, 64 weeks
Time frame: baseline, 24 weeks, 40 weeks, 64 weeks
Time frame: baseline, 24 weeks, 40 weeks, 64 weeks
Time frame: baseline, 24 weeks, 40 weeks, 64 weeks
Time frame: baseline, 24 weeks, 40 weeks, 64 weeks
Hanmi Pharmaceutical Company Limited
Industry
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04731688
Body Weight, Body Weight Changes
San Luis Obispo, California, United States
View Trial DetailsNCT00687115
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT02896140
Body Weight, Diabetes Mellitus
Boston, Massachusetts, United States
View Trial DetailsNCT07204483
Behavior, Behavioral Symptoms
Yomitan, Okinawa, Japan
View Trial Details